Mandate

Vinge advised Forbion Capital Partners in connection with investment in Cadoz AB

May 10, 2010

Cardoz AB based in Stockholm has received a capital injection of SEK 100 million. The investment has been made by the Dutch venture capital company, Forbion Capital Partners and the Spanish venture capital company, Ysios Capital Partners together with the existing owner the Swedish venture capital company, HealthCap, which also helped to start the company.

Cardoz develops anti-inflammatory pharmaceuticals to combat heart and vascular disorders. The capital contribution is primarily intended for the execution of a clinical phase II trial of a new drug to combat abdominal aorta aneurism (AAA). At present there are no drugs which combat AAA.

Vinge’s team consisted of responsible partner Johan Winnerblad and Johan Larsson who acted as project manager.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026